{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004174","form_type":"8-K","ticker":null,"cik":"0001261249","company_name":"AGILE THERAPEUTICS INC","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.630199+00:00","generated_at":"2026-06-04T05:48:50.768651+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agile Therapeutics FY2023 rev $19.6M (+80% YoY); GAAP net loss $14.5M; Nasdaq delisted; debt paid","bullets":["Full year 2023 net revenue $19.6M, up 80% YoY; Twirla demand up 131% to 243,841 cycles.","GAAP net loss $14.5M ($6.71/share); non-GAAP net loss $21.2M ($9.84/share); OPEX down 33% to $30.5M.","Cash $2.5M at Dec 31, 2023; raised $4.8M via warrant exercise in Feb 2024; paid off Perceptive Advisors debt in Q1 2024.","Delisted from Nasdaq on Mar 25; now trading on OTC under AGRX; does not expect impact on business.","Twirla demand rebounding in Q1 2024; January retail cycles (26,464) highest single month since launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004174","json":"https://secwatch.observer/filing/0001558370-24-004174.json","markdown":"https://secwatch.observer/filing/0001558370-24-004174.md","text":"https://secwatch.observer/filing/0001558370-24-004174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1261249/000155837024004174/0001558370-24-004174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1261249/000155837024004174/agrx-20240328x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:48:50.768651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb6d942893c8b326ef7bdb1046b3bb1478a0fdcd","claim":"AGILE THERAPEUTICS INC reported the three months and fiscal year ended December 31, 2023 results: revenue Net revenue for the fourth quarter 2023 was $3.6 million.","evidence_excerpt":"On March 28, 2024, Agile Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and an update on the Company’s operations.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1261249/000155837024004174/0001558370-24-004174-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"Net revenue for the fourth quarter 2023 was $3.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}